恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎的临床效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (30 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of Entecavir combined with Diammonium Glycyrrhizinate in the treatment of chronic hepatitis B.Methods From January 2017 to January 2019，a total of 80 cases chronic hepatitis B in our hospital were selected.They were divided into observation group (n=40) and control group (n=40) according to the random number table method.The control group was treated with Diammonium Glycyrrhizinate Enteric Coated Capsules,and the observation group was treated with Entecavir Tablets combined with Diammonium Glycyrrhizinate Enteric Coated Capsules.The liver function indexes before and after treatment and total effective rate were compared between the two groups.Results There were no significant differences in aspartate aminotransferase (AST) and alanine aminotransferase （ALT) between the two groups before treatment (P＞0.05); after treatment,AST and ALT in the observation group were lower those in the control group,the differences were statistically significant (P＜0.05); the ALT normalization rate,HBV-DNA negative conversion rate,HBeAg negative conversion rate and HBeAg/anti HBe conversion rate of the observation group were 92.5%,95.0%,67.5,27.5% respectively,higher than those of the control group of 72.5%,80.0%,45.0%,7.5%,the differences were statistically significant (P＜0.05).Conclusion Entecavir combined with Diammonium Glycyrrhizinate in the treatment of chronic hepatitis B can improve the liver function of the patients significantly,with reliable effect,and can be popularized.

Key words： Entecavir Diammonium Glycyrrhizinate Chronic hepatitis B Liver function HBV-DNA turning negative

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Xiu-huo
	LUO Xian-xin
	CHEN Xing

Cite this article:

HUANG Xiu-huo,LUO Xian-xin,CHEN Xing. Clinical effect of Entecavir combined with Diammonium Glycyrrhizinate in the treatment of chronic hepatitis B[J]. 中国当代医药, 2020, 27(31): 53-55.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I31/53

[1]	陈杰，高凌燕，王江.恩替卡韦治疗慢性乙型肝炎患者的效果与不良反应分析[J].山西医药杂志，2020，49（2）：195-197.
[2]	焦向鲲，高玉金，王春颖，等.恩替卡韦联合长效干扰素治疗HBeAg 阳性慢性乙型肝炎的临床观察[J].中国药房，2017，28（32）：4552-4555.
[3]	侯丽娟，李玉华，王宏伟，等.恩替卡韦治疗慢性乙型肝炎的疗效[J].中华医院感染学杂志，2019，29（21）：3242-3245，3255.
[4]	范倩燕，鲍彩丽，俞莹，等.恩替卡韦治疗不同乙型肝炎病毒基因型慢性乙型肝炎疗效分析[J].中国药业，2017，26（17）：43-45.
[5]	中华医学会肝病学分会.慢性乙型肝炎诊断标准（2015年版）[J].中西医结合肝病杂志，2015，25（6）：70-72.
[6]	张丽翠，钟晨，张砚，等.恩替卡韦治疗慢性乙型病毒性肝炎患者的临床研究[J].中国临床药理学杂志，2019，35（20）：2539-2542.
[7]	梁丽，李红艺，任江波，等.长期恩替卡韦抗病毒治疗对老年慢性乙型肝炎患者肾脏功能的影响[J].中华老年医学杂志，2019，38（11）：1258-1261.
[8]	张晓艳，张海涛，杨立新，等.恩替卡韦联合长效干扰素治疗HBeAg 阳性慢性乙型肝炎临床研究[J].中国药业，2019，28（18）：35-37.
[9]	张希顺，申雪粉，王雷，等.恩替卡韦应答不佳慢性乙型肝炎患者联合干扰素治疗效果观察[J].河北医药，2019，41（14）：2146-2149，2153.
[10]	张亚峰，王鹏.恩替卡韦与阿德福韦酯对慢性乙型肝炎的成本-效果分析[J].药物评价研究，2018，41（12）：2322-2325.
[11]	申恩华，王茉莉，王立红，等.恩替卡韦和富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎及乙型肝炎肝硬化抗病毒效果[J].中国医药导报，2018，15（28）：70-73.
[12]	吴取梅，赵久法.恩替卡韦治疗慢性乙型肝炎病毒感染的疗效观察及其影响因素[J].蚌埠医学院学报，2017，42（12）：1604-1608.
[13]	李丽丽.HBV 血清标志物及HBV DNA 定量检测对乙肝病毒感染的诊断[J].河南医学研究，2019，21（16）：148-150.
[14]	梁建英，杜元平，张昌艳，等.硫普罗宁联合恩替卡韦治疗慢性乙型肝炎的临床研究[J].现代药物与临床，2018，33（7）：1711-1714.
[15]	黄娇凤，林苏，王明芳，等.恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效及其对肝组织脂肪变的影响[J].实用肝脏病杂志，2018，21（6）：863-867.
[16]	张伟.慢性乙型肝炎抗病毒治疗中恩替卡韦和干扰素的应用观察[J].检验医学与临床，2017，14（Z2）：204-205.